Entrada Therapeutics (TRDA) 10% Owner MPM BioVentures Sells Shares

What Happened
MPM BioVentures 2018, L.P. — reported as a 10% owner in Entrada Therapeutics (TRDA) — sold a total of 62,714 shares in open-market transactions across Aug 24–26, 2026, producing gross proceeds of about $461,546. Sales by day: 21,623 shares at a weighted avg $7.34 ($158,713) on Aug 24; 26,522 shares at $7.54 ($199,976) on Aug 25; and 14,569 shares at $7.06 ($102,857) on Aug 26. These were sales (S) — not purchases or exercises — and represent liquidity by affiliated funds rather than a direct executive buy/sell signal.

Key Details

• Dates & prices: Aug 24 (21,623 sh @ $7.34), Aug 25 (26,522 sh @ $7.54), Aug 26 (14,569 sh @ $7.06). Total ~62,714 shares for ~$461,546.
• Price ranges: filing notes sale prices ranged roughly from $6.97 to $7.6421 across the transactions; per-transaction weighted averages are listed above. The filer will provide per-share price breakdowns to the SEC staff on request.
• Holdings after sales: affiliated MPM funds continue to hold several million TRDA shares in aggregate (footnotes show combined holdings around ~4.3M shares across related funds).
• Parties & structure: sales were allocated among multiple affiliated entities (BV 2014, BV 2018 and related B and AM vehicles); MPM BioVentures GP/LLC entities act as general partners/managers and named managing directors are Messrs. Evnin, Foley and Gadicke. Each reporting person disclaims beneficial ownership except to the extent of pecuniary interest (see footnotes).
• Filing timeliness: Reported period begins Aug 24 and the Form 4 was filed Aug 26, 2026 — consistent with a timely filing (no late-filing indication).

Context

• This filing involves a large institutional/VC owner, not an individual executive; such sales often reflect fund-level liquidity or portfolio management rather than an officer/director trading on inside knowledge.
• No options were exercised and no awards or gifts were reported — these were straight sales (code S).
• The filing provides footnotes identifying exactly which affiliated funds sold shares and how many; consult the Form 4 for the full allocation and any additional details requested from the filer.